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Abstract
Background: Newborns display distinct immune responses that contribute to susceptibility to infection and reduced
vaccine responses. Toll-like receptor (TLR) agonists may serve as vaccine adjuvants, when given individually or in
combination, but responses of neonatal leukocytes to many TLR agonists are diminished. TLR8 agonists are more effective
than other TLR agonists in activating human neonatal leukocytes in vitro, but little is known about whether different TLR8
agonists may distinctly activate neonatal leukocytes. We characterized the in vitro immuno-stimulatory activities of a novel
benzazepine TLR8 agonist, VTX-294, in comparison to imidazoquinolines that activate TLR8 (R-848; (TLR7/8) CL075; (TLR8/
7)), with respect to activation of human newborn and adult leukocytes. Effects of VTX-294 and R-848 in combination with
monophosphoryl lipid A (MPLA; TLR4) were also assessed.
Methods: TLR agonist specificity was assessed using TLR-transfected HEK293 cells expressing a NF-kB reporter gene. TLR
agonist-induced cytokine production was measured in human newborn cord and adult peripheral blood using ELISA and
multiplex assays. Newborn and adult monocytes were differentiated into monocyte-derived dendritic cells (MoDCs) and TLR
agonist-induced activation assessed by cytokine production (ELISA) and co-stimulatory molecule expression (flow
cytometry).
Results: VTX-294 was ,100x more active on TLR8- than TLR7-transfected HEK cells (EC50, ,50 nM vs. ,5700 nM). VTX-294-
induced TNF and IL-1b production were comparable in newborn cord and adult peripheral blood, while VTX-294 was ,
1 log more potent in inducing TNF and IL-1b production than MPLA, R848 or CL075. Combination of VTX-294 and MPLA
induced greater blood TNF and IL-1b responses than combination of R-848 and MPLA. VTX-294 also potently induced
expression of cytokines and co-stimulatory molecules HLA-DR and CD86 in human newborn MoDCs.
Conclusions: VTX-294 is a novel ultra-potent TLR8 agonist that activates newborn and adult leukocytes and is a candidate
vaccine adjuvant in both early life and adulthood.
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Introduction
Newborns display distinct immune responses that leave them
vulnerable to higher rates of infections as compared to older
children and adults [1], with over 2,000,000 deaths per year
worldwide due to infection in those less than 6 months of age [2].
In particular, neonatal deficiencies of innate cellular immune
responses include a decreased production of interferons, IL-12p70,
TNF and other proinflammatory/Th1-polarizing cytokines [3].
Divergent neonatal immune responses also pose a challenge to
efforts to enhance early life immunization, which is a key global
health strategy [4]. Lack of effective immunization strategies in the
neonatal period (first 28 days of life) leads to a window of
susceptibility to infections in newborns and infants lasting several
months. For the past decade, there has been an ongoing focus on
understanding the mechanisms by which the immune system of
very young is distinct from adults, particularly in response to
immunization [5]. New insights into the ontogeny of innate
immunity are informing development of age-specific adjuvanted
vaccine formulations [6,7,8], with safety and efficacy remaining
central priorities [9]. The coming decade is likely to focus on
developing technologies that overcome or circumvent these
immunological obstacles to the development of more effective
early life vaccines [2].
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58164A promising approach to enhancing immunity of newborns and
infants is to use TLR agonists as novel stand-alone immunomod-
ulators and/or as adjuvants in vaccine design [10]. Indeed, TLR
agonists have been unknowingly used for decades in vaccines such
as Haemophilus influenzae type b (HIb) vaccine containing Neisseria-
derived outer membrane proteins (TLR2), Bacille Calmette-
Gue ´rin (Mycobacterium bovis; TLR 2, 4 and 8) [11], and certain
hepatitis B vaccines that contain lipid A (TLR4) [12]. First
generation vaccines, including those consisting of inactivated or
attenuated virus, contained inherent TLR7 and/or TLR8
adjuvant activity [13]. Both the inactivated polio and Japanese
Encephalitis vaccines, which were introduced in 1955 and 1968,
respectively, contained single stranded RNA (ssRNA) TLR7/8
agonists. Additionally, the highly effective live attenuated yellow
fever vaccine 17D (YF-17D) activates multiple dendritic cell (DC)
subsets via TLR2, TLR7, TLR8, and TLR9 [14] and exhibits
activity in children [15].
Neonatal whole blood, cord blood mononuclear cells (CBMCs)
and monocytes demonstrate impaired TNF responses to agonists
of TLR1–7, most notability for TLR2/6 and TLR4 activation
[16]. In contrast, TLR8 agonists may possess unique activity in the
very young [6,17,18,19]. The TLR 7, -8 and -9 subfamily is
endosomal and activated by nucleic acids [20,21]. Single stranded
viral RNAs, such as those of influenza and human immunodefi-
ciency viruses, are natural agonists for TLR7 and TLR8 [22].
Both human dermal and myeloid DC, as well as T cells, express
TLR8 [13,23]. TLR8 agonists, including R848, induced adult-
level TNF and IL-12p40/70 production in neonatal WB and
CBMCs [18]. Additionally, TLR8 (including dual TLR7/8)
agonists, such as those of the synthetic anti-viral imidazoquinoline
(IMQ) family [24] and ssRNAs, activate robust immune responses
in newborn cells relative to other TLR agonists by a mechanism
refractory to the endogenous suppressive factors, such as
adenosine, present in neonatal blood plasma [25,26,27]. However,
the potential of the TLR8 pathway, including possible differences
in immunologic activity between different TLR8 agonists, is
incompletely characterized [28].
VentiRx Pharmaceuticals (Seattle, WA) has produced a series of
novel low molecular weight (400 – 475 Da) synthetic benzazepine
derivatives that selectively activate cells via TLR8. Due to its
ability to re-orient immune responses towards Th1 immunity, the
TLR8 agonist VTX-1463 is in development for the treatment of
allergic rhinitis and has shown significant symptom reduction in
atopic individuals [29]. The TLR8 agonist VTX-2337 activates
monocytes, DCs and NK cells, induces IFN-c production and
increased cytolytic activity, and is being developed as an
immunotherapy in multiple oncology indications [30]. In the
present study, we assessed novel VentiRx benzazepine compounds
(VTXs), characterized their specificity using TLR-transfected
human embryonic kidney (HEK) cells, and have evaluated their
bioactivity towards human newborn and adult primary leukocytes.
We find that VTX-294 is an ultra-potent TLR8-selective agonist
with greater potency and activity than IMQs in both neonatal and
adult leukocytes and MoDCs, suggesting that it may be a
particularly attractive candidate as an adjuvant towards neonatal
leukocytes.
Materials and Methods
Ethics Statement
Non-identifiable cord blood samples were taken with approval
from the Ethics Committee of The Brigham & Women’s Hospital,
Boston, MA (protocol number 2000-P-000117). All blood samples
from adult patients included in the experiments provided written
informed consent with approval from the Ethics Committee of
Boston Children’s Hospital, Boston, MA (protocol number X07-
05-0223). All experiments were performed in accordance with
relevant institutional and national guidelines, regulations and
approvals.
TLR Agonists and Assay Reagents
The following commercially-available TLR agonists were used
at the concentrations noted in the figure legends: MPLA (TLR4),
R848 (TLR7/8), CL075 (TLR8/7) (InvivoGen, San Diego, CA).
VTX-217 (a negative control with a similar core structure to other
VTX compounds but with modifications to make inactive towards
TLRs 7/8), VTX-744 (TLR8), VTX-087 (TLR8) and VTX-294
(TLR8) (VentiRx Pharmaceuticals, Inc., Seattle, WA, USA) were
produced using a method of synthesis of substituted benzazepine
derivatives [31]. TLR agonists (other than MPLA) were verified to
be free of endotoxin (,1 EU/ml) as measured by the Limulus
amoebocyte lysate (LAL) assay per the manufacturer’s instructions
(Charles River, Wilmington, MA). TLR agonists were prepared in
DMSO (Sigma-Aldrich, St. Louis, MO) as outlined in Figure 1A,
and DMSO controls employed to control for any potential vehicle
effects on cell activation.
Human TLR Expressing HEK293 Cell Assays
Human embryonic kidney cells (HEK293) expressing TLR2,
TLR3, TLR4, TLR5, TLR7, TLR8, or TLR9 were purchased
from InvivoGen (San Diego, CA) and cultured in DMEM
(Cambrex, Walkersville, MD) containing 4.5 g/L L-glucose
(Sigma–Aldrich, St. Louis, MO) and 10% fetal bovine serum
(FBS) (Gibco). The activity of specific TLR agonists was assessed
using the secretory embryonic alkaline phosphatase (SEAP)
reporter gene that is linked to NF-kB activation in response to
TLR stimulation. Measurement of SEAP activity was determined
using the Quanti-blue
TM substrate (InvivoGen) after TLR agonist
treatment for 18–24 hours using a Victor 3V 1420 Multilabel
Counter (Perkin Elmer) to measure OD at 650 nM.
Human Blood
Peripheral blood was collected from healthy adult volunteers,
while human newborn cord blood was collected immediately after
Cesarean section delivery of the placenta. Births to HIV-positive
mothers were excluded. Human experimentation guidelines of the
U.S. Department of Health and Human Services, The Brigham &
Women’s Hospital, and Boston Children’s Hospital were ob-
served, following protocols approved by the local institutional
review boards. Human blood was anti-coagulated with 15–20
units/ml pyrogen-free sodium heparin (American Pharmaceutical
Partners, Inc., Schaumberg, IL). All blood products were kept at
room temperature and processed within 4 hrs of collection.
Blood Sample Processing and in vitro Stimulation
For assessment of TLR agonist activity in whole blood, we used
an adaptation of the method of Kollmann et al. [32,33]. Neonatal
cord blood or adult whole blood (WB) was mixed 1:1 with sterile
pre-warmed (37uC) RPMI 1640 medium (Invitrogen, Carlsbad,
CA) and 180 mL of the 1:1 suspension was added to each well of a
96 well U-bottom plate (Becton Dickinson, Franklin Lakes, NJ,
USA) containing 20 ml freshly prepared specific TLR agonists at
10x the final concentration. Suspensions containing 200 ml/well
were gently mixed by pipetting and incubated for 2–24 h at 37uC
in a humidified incubator at 5% CO2. After culture, plates were
centrifuged at 5006g and 110–150 ml of supernatant was carefully
removed by pipetting without disturbing the cell pellet. Superna-
Ultra-Potent and Selective TLR8 Agonist VTX-294
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e58164tants derived from human leukocyte stimulations were assayed by
ELISA for TNF (BD Biosciences, San Jose, CA, USA) and IL-1b
(eBiosciences, San Diego, CA). Additionally, WB supernatants
were analysed by Multi-Analyte Profiling (MAP). Briefly, super-
natant samples were frozen at 280uC and submitted to Myriad
RBM (Austin, TX, USA) for screening with a modified Human
InflammationMAPH v. 1.6 antigen panel, which analyzed the
samples for the presence of 98 analytes associated with inflam-
mation. The minimum threshold for each analyte was set at the
minimum detectable dose for that particular assay (defined as
three standard deviations above the mean background).
Monocyte-derived Dendritic Cells (MoDCs)
Heparinized human newborn cord blood or adult peripheral
blood was layered onto Ficoll-Hypaque gradients (Ficoll-Paque
PREMIUM, GE Healthcare, Waukesha, WI) to collect CBMC or
peripheral blood mononuclear cell layers (PBMC), respectively.
Monocytes were isolated from mononuclear cell fractions by
positive selection by magnetic microbeads according to the
manufacturer’s instructions (Miltenyi Biotec, Auburn, CA) using
CD14 or CD33 as a pan-marker for monocytes [34]. Monocyte
preparations were .95% pure as assessed by flow cytometry for
CD14 as previously described [25]. Isolated monocytes were
cultured in tissue culture dishes at 10
6 cells/ml in RPMI 1640
media containing fresh 10% autologous plasma, supplemented
with rhIL-4 (50 ng/ml) and rhGM-CSF (100 ng/ml) (R&D
Systems, Minneapolis, MN) with one additional supplement of
fresh media and cytokines at day 3 of culture. After 5–6 days,
immature MoDCs (HLA-DR
+, CD14
2, DC-SIGN
+ as measured
by flow cytometry) of .90% purity were harvested by gently
pipetting only the loosely adherent fraction and re-plated (10
5
cells/well) in 96-well U-bottom plates in the presence or absence of
TLR agonists.
Flow Cytometry
Following TLR agonist stimulation, MoDCs were resuspended
in staining buffer (16PBS, 0.5% human serum albumin (HSA))
and stained for 30 min at 4uC in the dark (1.5610
5/per staining)
with fluorophore-labeled antibodies (FITC/HLA-DR and PE/
CD86) (BD Biosciences). Cells were then centrifuged, washed,
fixed (1% paraformaldehyde (PFA)) and filtered prior to flow
cytometry analysis using a MoFlo Legacy cytometer (DakoCyto-
mation, Fort Collins, CO) and analyzed using FlowJo software
(Tree Star). MFI fold change was plotted after subtraction of the
MFI of equivalent samples stained with an isotype control
antibody.
Statistical Analyses and Graphics
Data were analyzed using Prism for MacIntosh v. 5.0b
(GraphPad Software Inc., San Diego, CA). Data in figures
represent means 6 SEM. p values ,0.05 were considered
significant. Normalcy was tested using the Shapiro-Wilk normality
test. For normal sample sets, two-tailed t-test or One-way ANOVA
with Bonferroni post-test were applied as appropriate. Non-
normal sample sets were analyzed by Kruskal-Wallis test with
Figure 1. VTX-294 activates the NF-kB pathway via TLR8. (A) Seven TLR agonists were compared. (B) Representative structures of the TLR7/8
agonists used in this study. HEK-293 cells transfected with (C) human TLR7 and (D) TLR8 and an NF-kB-driven reporter SEAP gene were stimulated for
18–24 h with TLR agonists. The y-axis shows the level of SEAP activity in the Quanti-blue
TM assay optical density (OD). The x-axis shows the
concentration of each compound in mM. Each data point represents the mean 6 SD of OD at 650 nm of triplicate culture wells. VTX-217 (black) is a
structurally matched negative control for VTX-744 (gray), VTX-087 (purple) and VTX-294 (red). The IMQ benchmarks R848 and CL075 are denoted in
blue and green, respectively.
doi:10.1371/journal.pone.0058164.g001
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test or by Mann-Whitney test, as appropriate.
Results
Specificity of VTX Agonists for Human TLR7 and TLR8
To assess the selectivity of novel VTX benzazepine compounds,
we characterized VTX-induced NF-kB activation in HEK-293
cells expressing human TLR7 or TLR8 in comparison to the
imidazoquinolines R848 (TLR7/8) and CL075 (TLR8) Figure 1
(C–D). As expected, R848 induced NF-kB activation in both
TLR7- and TLR8-transfected HEK293 cells. CL075 showed
greater activation of NF-kB in TLR8- compared to TLR7-
transfected cells at the highest concentration tested. Similarly, the
three VTX compounds VTX-744, VTX-087 and VTX-294
demonstrated activation of NF-kB in TLR8 transfected cells, with
VTX-294 also modestly activating TLR7 transfected cells at the
highest concentration tested. The potency of the VTX compounds
tested was assessed by comparing EC50 the concentration of
agonist at which half maximal activation of NF-kB was observed
in TLR8-transfected cells. This analysis indicated the following
rank of potencies: VTX-294 (EC50 0.05 mM).VTX-087
(0.54 mM).VTX-744 (1.68 mM).CL075 (4.57 mM).R848
(5.12 mM; Table S1). The structurally similar negative control
compound, VTX-217, did not induce activation of NF-kBi n
either TLR7- or TLR8-transfected cells. Additionally, none of the
VTX agonists tested activated TLR2 (the receptor for lipo-
peptides), TLR3 (double-stranded RNA), TLR4 (lipopolysaccha-
ride (LPS)), TLR5 (bacterial flagellum) or TLR9 (unmethylated
CpG dinucleotide-containing DNA) (Figure S1).
The Novel TLR Agonist VTX-294 Potently Activates
Human Newborn and Adult Leukocytes
We tested the ability of VTX agonists to induce dose dependent
cytokine production in human neonatal and adult blood (Figure 2).
In line with the HEK293 data in Figure 1 (C–D), the negative
control compound VTX-217 did not demonstrate activation of
either human neonatal cord or adult peripheral blood (data not
shown). As VTX-294 was the most potent of all three VTX
compounds, we tested the dose-dependent cytokine induction of
VTX-294 compared with MPLA, a TLR4 agonist whose
congeners are adjuvant components of vaccines licensed by both
the U.S. Food and Drug Administration (FDA) and European
Medicines Agency (EMA), and two imidazoquinoline TLR agonist
adjuvants (Figure 2). VTX-294 activated neonatal and adult blood
in a dose-dependent manner, significantly inducing production of
TNF and IL-1b over baseline (p,0.001). In both newborn cord
and adult peripheral blood, MPLA (TLR4), R848 (TLR7/8) and
CL075 (TLR8) significantly induced production of TNF and IL-
1b, in a dose dependent manner (Figure 2). When compared to
R848 at 0.1 mM, VTX-294 demonstrated greater efficacy,
stimulating greater TNF and IL-1b production in neonatal blood
Figure 2. VTX-294 is more potent and effective than R-848 in inducing TNF and IL-1b in whole blood. Human neonatal and adult blood
was cultured for 6 h with MPLA (TLR4), R848 (TLR7/8), CL075 (TLR8) and VTX-294 (TLR8) and supernatants collected for TNF or IL-1b ELISA. Compound
concentrations are shown in mM, except for MPLA, which are shown in ng/ml. Data are shown as mean 6 SEM of n=5–8. For between-group
analyses, Wilcoxon signed-rank test was applied to compare VTX-294 median value to the other compounds at a given concentration. Statistical
significance is denoted as follows: *p,0.05 and **p,0.01, with black star(s) for comparison to MPLA, blue star(s) for comparison to R848 and green
star(s) for comparison to CL075.
doi:10.1371/journal.pone.0058164.g002
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in inducing IL-1b production in adult WB (p,0.05). Greater
potency of VTX-294 as compared to R848 and CL075 was also
noted for adult TNF production, but did not reach significance
(p=0.054). Overall, VTX-294 demonstrated the greatest potency
(i.e. lowest EC50 values) of all agonists tested for both TNF and IL-
1b production in newborn cord and adult peripheral blood (Table
S1). With respect to efficacy of inducing cytokine production, the
maximum cytokine levels produced at higher agonist concentra-
tions of VTX-294 (e.g., 100 mM) was similar to those induced by
R848 and CL075 (Table S2).
Comparison of TLR Agonist-induced TNF and IL-1b
Production in Newborn and Adult Blood
Our results demonstrate an impaired newborn WB TNF
response to MPLA by between group comparison (newborn vs.
adult) (Figure 3 A, p,0.01). In line with previous findings on the
unique efficacy of TLR8 agonists in newborn blood [18], we
demonstrated a preservation of responses to R848 and CL075,
both inducing TNF production in newborn cord blood at
concentrations equal to or greater than that in adult blood
(p,0.01 and p,0.001 respectively) by between group comparison
(newborn vs. adult). VTX-294 not only induced greater concen-
trations of TNF in newborn WB compared to adults (p,0.001),
but also did so at individual doses (newborn vs. adult) as low as
1 mM( p ,0.05). In contrast, R848 was not more effective at
inducing TNF in newborn relative to adult WB, while CL075
demonstrated greater efficacy at inducing TNF at 100 mM than
VTX-294. IL-1b production followed a similar pattern, with
VTX-294 inducing a greater concentration of IL-1b in newborn
cord blood compared to adult peripheral blood at concentrations
of .1 mM( p ,0.01). CL075- and R848-induced IL-1b production
was significantly increased in newborn compared to adult WB at
10 mM( p ,0.05) (Figure 3 B).
Multi-Analyte Comparison of Agonist Combination-
induced Cytokine Production in Newborn and Adult
Blood
We next employed a multiplexed bead array-based approach to
provide a broader view of differences between newborn and adult
TLR agonist-induced inflammatory biomarkers after 6 h of
stimulation (Figure 4 and Figure S2). This approach confirmed
that compared to adult blood, newborn blood contained: 1) lower
basal CRP concentrations (Figure 4 A), 2) greater human growth
hormone [35] (Figure S2 A), 3) increased basal CXCL-8 (IL-8)
concentrations [36], and 4) greater TLR4-mediated production of
IL-10 (Figure 4 B) [32]. We also confirmed that TLR7/8 agonists
induce similar concentrations of IL-12p40 in both newborn and
adult WB [32], although IL-12p70 production in neonates was
reduced [37] (Figure 4 C–F).
Newly identified differences in newborn as compared to adult
blood, included a consistent increase in both EN-RAGE
(extracellular newly identified RAGE-binding protein) and mye-
loperoxidase (MPO) under all stimulated conditions (Figure S2).
The increase in MPO may reflect the greater number of
Figure 3. VTX 294 induces greater cytokine responses in newborn cord than adult peripheral blood. Human neonatal and adult blood
was cultured for 6 h with MPLA (1, 10, 100, 1000 ng/ml), CL075, R848 and VTX-294 (all 0.1, 1, 10, 100 mM) and supernatants collected for TNF or IL-1b
ELISA. Mean 6 SEM of agonist-induced cytokine production are shown for n=5–6. For comparisons between overall groups (newborn vs. adult),
Kruskal-Wallis test with Dunn’s post test were applied, with significance denoted as
++p,0.01,
+++p,0.001. For analyses at individual doses (newborn
vs. adult), unpaired Mann-Whitney test was applied at each concentration and statistical significances are denoted as follows: *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0058164.g003
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mediated production of oncostatin M (OSM), an IL-6 family
cytokine, was greater in newborn, as compared to adult blood for
MPLA (100 ng/ml), R848 (10 mM) and VTX-294 (10 mM; Figure
S2). Conversely, under all conditions tested, newborn cord blood
Figure 4. Comparison of TLR agonist-induced inflammatory biomarker production in newborn and adult blood. Human neonatal
(blue) and adult (red) WB samples were cultured for 6 h with (A) vehicle (B) MPLA (TLR4), (C–D) R848 (TLR7/8) and (E–F) VTX-294 (TLR8) and
supernatants recovered for analysis by Multi-Analyte Profiling (MAP), with a modified Human Inflammation MAP v. 1.6-antigen panel. Cytokine
responses of 25 analytes (pg/ml) are represented in radar plots. Data are shown as mean 6 SEM for n=3.
doi:10.1371/journal.pone.0058164.g004
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(MMP-3) (Figure S2).
VTX-294 Induces Greater Cytokine Responses than R848
in Human Neonatal Blood
At the lowest tested concentration (0.1 mM), VTX-294 induced
greater concentrations of nearly all cytokines tested than R848
(Figure 5 A). Specifically, when expressed as fold change over
R848 induction, VTX-294 induced .10 fold more TNF, IL-1b
and IL-10 and .5 fold more IL-6 and IL-12p40 (Figure 5 A).
Compared to R848, VTX-294 induced greater production of
multiple chemokines, including CCL3 (MIP-1a; .1000 fold),
CCL4 (MIP-1b), CCL-2 (MCP-1) and CXCL-8 (IL-8) (all .5
fold), CSF3 (G-CSF) and CRP (both .5 fold) (Figure 5 A).
As combinations of TLR agonists may have synergistic immune
enhancing effects and several vaccine formulations employ
combinations of adjuvants, we tested combinations of MPLA with
either R848 or VTX-294 in newborn WB. Specifically, when
expressed as fold change over MPLA/R848 induction, MPLA/
VTX-294 induced .5 fold more TNF and IL-1b (Figure 5 B). We
further assessed the effects of increasing concentrations of MPLA
(Figure 5 C–D) with fixed concentrations of R848 and VTX-294
(both 0.1 mM) measuring these two key cytokines. We found that
VTX-294 acted in synergy with MPLA, particularly at lower
concentrations of the MPLA. Similarly, we characterized adult
WB comparing R848 and VTX-294 (both 0.1 mM) (Figure S3 A)
with or without co-addition of MPLA (Figure S3 B–D).
To further characterize the immunostimulatory potential of
VTX-294, we assessed dose-dependent stimulation of newborn
WB measuring 50 analytes, at concentrations of 0.1–10 mM
(Figure 6 A–B). When graphed as fold change over unstimulated,
a dose-dependent induction was clearly evident for multiple
cytokines including TNF, IL-1b, IL-1a, IL-1Ra, IL-6, CXCL-8
(IL-8), G-CFS, IL-12p40 and IL-10 (Figure 6 A). The low dose of
VTX-294 (0.1 mM) induced a similar cytokine profile to MPLA-
mediated responses (Figure A4 A–B). In newborn whole blood, a
Figure 5. Whether tested alone or together with MPLA, VTX-294 has greater cytokine-inducing potency than R848 in human
neonatal blood. Human neonatal WB samples were cultured for 6 h with VTX-294 or R848 (both 0.1 mM) and supernatants recovered for analysis by
Multi-Analyte Profiling (MAP), with a modified Human Inflammation MAP v. 1.6-antigen panel. Cytokine responses of 25 analytes are represented in
radar plots demonstrating fold-change of (A) 0.1 mM VTX-294 (red) over 0.1 mM R848 (blue), or (B) WB concurrently stimulated in the presence of
100 ng/ml MPLA with 0.1 mM VTX-294 (red) over 100 ng/ml MPLA with 0.1 mM R848 (blue). TNF (C) and IL-1b (D) responses in neonatal WB are shown
for VTX-294 (0.1 mM), R848 (0.1 mM) and buffer control added to increasing concentrations of MPLA (0–1,000 ng/ml) are shown. Data are shown as
mean 6 SEM for n=4. Statistical significance was determined using paired t-test comparing MPLA/VTX-294 treated compared to MPLA/R848 (C, D);
*p,0.05.
doi:10.1371/journal.pone.0058164.g005
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1b, IL-1a, IL-12p40, IL-10 and TNF in comparison to MPLA
alone (Figure S4 C–D). VTX-294-assocaited enhancements of IL-
12p70, IL-25 and IFN-c production were selectively evident in
adult whole blood.
VTX-294 Potently Activates Human Neonatal MoDCs
As antigen-presenting cells are key targets for candidate
adjuvants, we next compared dose-dependent responses of human
neonatal MoDCs to MPLA (1–100 ng/ml), R848 and VTX-294
(both 0.1–10 mM) with respect to production of TNF, as well as
expression of HLA-DR and the co-stimulatory molecule CD86
(Figure 7). MPLA induced dose-dependent TNF production at
both 10 and 100 ng/ml (p,0.05) compared to unstimulated DCs.
Whereas VTX-294 induced MoDC TNF production at concen-
trations as low as 0.3 mM, R848 induced significant levels of this
cytokine only at 10 mM. The greater potency of VTX-294
compared to R848 in neonatal MoDCs was also observed with
respect to induction of surface HLA-DR and the significantly
increased CD86 expression (Figure 7 B, C).
Discussion
Multiple licensed vaccines induce effective activation of innate
immune responses by incorporating live attenuated pathogens or
microbial products now known to contain TLR agonists [38].
However, with the continued development and use of inactivated
subunit based vaccines, adjuvants have become increasingly
important in order to overcome underdeveloped and distinct
immune responses in immunocompromised populations such as
newborns and infants [4]. Recent studies highlight that immuno-
logic signatures can predict vaccine efficacy [14], suggesting that
characterizing the immunostimulatory properties of candidate
adjuvants may provide insight into their translational potential.
We report here a broad characterization of secreted cytokine/
chemokine and inflammatory proteins in a neonatal whole blood
system in response to the ultra-potent and selective TLR8 Agonist
Figure 6. VTX-294 induces dose-dependent production of multiple soluble plasma analytes. Human neonatal WB samples were cultured
for 6 h with VTX-294 (0.1–10 mM) and supernatants recovered for analysis by Multi-Analyte Profiling (MAP), with a modified Human Inflammation
MAP v. 1.6-antigen panel. Responses for 50 analytes (pg/ml) are represented in radar plots showing fold-change of VTX-294 (red) over un-stimulated
(black). Radar plots show (A) 25 immunomodulatory cytokines and chemokine’s, and (B) 25 hormones, growth and stress factors.
doi:10.1371/journal.pone.0058164.g006
Figure 7. VTX-294 potently activates human neonatal MoDCs. Stimulation of neonatal MoDCs for 24 h. Supernatants collected for (A) TNF
ELISA and DCs for measurement of (B) HLA-DR and (C) CD86 expression by flow cytometry. Dose dependent surface expression of co-stimulatory
markers with MPLA (1, 10, 100 ng/ml), R848 (0.1, 0.3, 10 mM) and VTX-294 (0.1, 0.3, 10 mM) is shown as mean fluorescent intensity (MFI) represented
as fold change over vehicle control (mean 6 SEM, n=3); *p,0.05.
doi:10.1371/journal.pone.0058164.g007
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towards TLR-mediated IL-6 and IL-10 responses [6,39] and have
also identified a similar neonatal bias towards TLR-mediated
CXCL-8 (IL-8) production. Characterizing the ontogeny of innate
immune responses may eventually inform development of
adjuvant vaccine formulations that are tailored to induce distinct
immune polarization for targeted neonatal and infant vaccines.
Additional distinct characteristics of neonatal innate cells, includ-
ing their reduced poly-functionality - the capability of an
individual cell to produce multiple cytokines simultaneously, likely
contribute to age-specific responses to TLR agonists [32].
TLR agonists are by now an established class of molecules with
potential vaccine adjuvant properties [40]. Indeed, the detoxified
LPS MPLA is a component of several licensed vaccines including
Cervarix that is approved for school-aged girls [41]. Although
both LPS and MPLA are agonists of TLR4, LPS triggers toxic
inflammation whereas MPLA is potently immunostimulatory, but
exhibits only 0.1 to 1% of the toxicity of its parent molecule and is
employed as an adjuvant in [42]. Newborns demonstrate an
impaired TNF response to LPS [32,43,44], but to our knowledge,
ours is the first study to compare MPLA-induced cytokine
production in cord and adult WB, revealing an impaired ability
of human neonatal blood leukocytes and MoDCs to mount
inflammatory responses to this TLR agonist.
We demonstrate for the first time that VTX-294, a small
benzazepine molecule that specifically and potently targets TLR8,
presents a unique opportunity for augmenting innate responses in
human newborns. TLR8 (including dual TLR7/8) are refractory
to the inhibitory neonatal adenosine system [27] and can therefore
overcome suboptimal newborn innate immune responses to
induce adult-level concentrations of several key cytokines
[45,46]. We demonstrate here that VTX-294 induced key
cytokines to concentrations comparable or greater than those
observed in adult blood. We believe this is the first reported TLR
agonist with such activity. Monocytes account for the majority of
TLR-, including TLR8-, mediated TNF production in whole
blood [18,25]. Additionally, as we compared TLR agonists in
blood derived form the same newborns, our data suggest that
robust responses induced by VTX-294 in newborn cord blood are
not due to differences in cellular composition but rather to the
inherent potency and efficacy of VTX-294. VTX-294 was not
only at least as effective as R848 in inducing cytokine production,
but also demonstrated ,10-fold greater potency in both WB and
MoDC systems. When comparing to MPLA in newborn and adult
blood, VTX-294 achieved higher maximum cytokine production
for TNF, IL-10 and IL-12p40. When added to human neonatal
MoDCs cultured in autologous plasma, VTX-294 was significantly
more potent than R848, induced greater maximum TNF
responses than MPLA. Even at the lowest concentrations tested
VTX-294 also tended to enhance surface expression of HLA-DR
and the co-stimulatory surface molecule CD86.
The potency of VTX-294 compared to R848 was also evident
in comparing combinations of these agonists with MPLA.
Combinations of TLR agonists may synergistically generate
optimal cytokine production important for adjuvant activity
[47]. For example, the live attenuated yellow fever vaccine YF-
17D is one of the most effective vaccines available and activates
multiple DC subsets via TLR2, 7, 8, and 9 [48]. Effective adjuvant
systems already exist that combine MPLA and alum (AS04,
developed by GlaxoSmithKline) [49] and in vitro studies with
defined combinations of TLR agonists re-enforce the potential of
such combined-adjuvant design [50,51]. More potent adjuvants
(or adjuvant combinations) may allow for antigen dose sparing or
may allow for single immunization strategies. Furthermore,
addition of TLR8 agonists, either in conjugated form or as a
freely soluble mixture, with vaccinal antigens enhances induction
of adaptive immune responses to a greater extent than do TLR4
or TLR9 agonists [52]. The impact of impaired MPLA responses
in early life may be seen in a recent phase 3 trial of the RTS,S/
AS01, an MPLA-adjuvanted malaria vaccine, that demonstrated
reduced efficacy in African infants aged 6 to 12 weeks [53], as
compared to those who were 5 to 17 months of age [54].
Overall, TLR8 agonists possess greater immunostimulatory
properties than agonists of other TLRs, not only at birth (cord
blood) but also in peripheral blood obtained during infancy, an
important phase of susceptibility and immunization schedules [6].
Future in vitro studies should focus on characterizing the
mechanisms underlying the potency and efficacy of VTX-294.
TLR8 is preferentially localized to the early endosome and the
endoplasmic reticulum but not to the late endosome or lysosome
[55]. Subsequent studies should determine if the VTX compounds
more effectively co-localize to these compartments. The phago-
some is an efficient platform for the recognition of diverse ligands,
sometimes involving co-operative interactions between TLR8 and
other TLRs [56], or even other classes of PRRs [57]. Additionally,
our lab has previously shown that CL075 can also activate DCs via
other classes of PRRs, such as the inflammasome [17], which is
supported by reports that imidazoquinolines can trigger induction
of inflammatory cytokines in the absence of TLR 7 or 8 agonist
activity [58]. Lastly, using molecular modeling studies, Govindaraj
et al. demonstrated that the binding affinity of the TLR8 agonist
R848 plays a key role in species-specificity [59]. Therefore, future
studies to determine the binding affinity of VTX-294 in
comparison with IMQs would be of interest. Future translational
studies should evaluate the safety and efficacy of vaccine
formulations containing TLR8 agonists in newborn animals,
focusing on non-human primates that express TLR8 with
structural and functional similarities to humans [60,61].
As safety and reactogenicity will be key considerations in
developing novel adjuvanted vaccines, both the immunological
and toxicological properties of novel vaccine formulations should
be benchmarked against currently used adjuvants such as
aluminum salts, oil emulsions, MPLA and approved pediatric
vaccines that contain endogenous TLR agonists, such as Bacille
Calmette–Gue ´rin [62]. Finally, novel means of localizing the
action of adjuvants, as has been done with the TLR7/8 agonist
3M-052, that contains a lipid tail modification of the imidazoqui-
noline that serves to localize its adjuvant action in tissues and
prevent systemic cytokine induction, may represent additional
approaches for enhancing safety while maintaining efficacy [63].
The data presented here support the potential adjuvant activity
of VTX-294 in vitro. Furthermore, VTX-294 activates human
newborn and adult leukocytes and MoDCs with potency and
efficacy that exceed several other TLR agonists, including MPLA.
VTX compounds can be produced to GMP quality in quantities
that allow clinical trials, and have been recently tested in a Phase I
clinical trials in patients with advanced solid tumors [30]. Our
results suggest that VTX compounds may have additional
applications as stand-alone immunomodulators or as vaccine
adjuvants that can enhance neonatal DC function.
Supporting Information
Figure S1 VTX agonists do not activate TLRs-2, -3, -4,
or -9. HEK-293 cells transfected with various human TLR and
an NF-kB-driven reporter SEAP gene were stimulated for 18–24 h
with TLR agonists. The y-axis shows the level of SEAP activity in
the Quanti-blue
TM assay by OD. The x-axis shows the
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I:C, LPS, and flagellin which are expressed in mg/ml, ng/ml and
mg/ml, respectively. Each data point represents the mean 6 SD of
OD at 650 nm of triplicate culture wells. The positive control
compound for each TLR is indicated in black.
(TIFF)
Figure S2 Comparison of TLR agonist-induced hor-
mones, growth and stress factors in newborn and adult
blood. Human neonatal (blue) and adult (red) WB samples were
cultured for 6 h with (A) vehicle (B) MPLA (TLR4), (C–D) R848
(TLR7/8) and (E–F) VTX-294 (TLR8) and analysis by Multi-
Analyte Profiling (MAP), with a modified Human Inflammation
MAP v. 1.6-antigen panel. Responses of 25 hormones, growth and
stress factors (pg/ml) are represented in radar plots. Data are
shown as mean 6 SEM for n=3.
(TIFF)
Figure S3 VTX-294 induces greater cytokine responses
than R848 in human adult blood. Human adult WB samples
were cultured for 6 h with VTX-294 or R848 (both 0.1 mM) and
supernatants recovered for analysis by Multi-Analyte Profiling
(MAP), with a modified Human Inflammation MAP v. 1.6-antigen
panel. Cytokine responses of 25 analytes (pg/ml) are represented
in radar plots showing fold-change of (A) VTX-294 (red) over
R848 (blue) alone (both 0.1 mM), or (B) WB concurrently
stimulated in the presence of 100 ng/ml MPLA with 0.1 mM
VTX-294 (red) over 100 ng/ml MPLA with 0.1 mM R848 (blue).
TNF (C) and IL-1b (D) responses in adult WB are shown for
VTX-294 (0.1 mM), R848 (0.1 mM) and buffer control added to
increasing concentrations of MPLA (0–1,000 ng/ml) are shown.
Data are shown as mean 6 SEM for n=4. Statistical significance
was determined using paired t-test comparing MPLA/VTX-294
treated compared to MPLA/R848 (C, D); *p,0.05.
(TIFF)
Figure S4 Comparison of MPLA, VTX-294 and combi-
natory MPLA-VTX-294-induced cytokines in newborn
and adult blood. Human neonatal (blue) and adult (red) WB
samples were cultured for 6 h. Cytokine responses of 25 analytes
(pg/ml) are represented in radar plots showing fold-change of (A)
un-stimulated vehicle to MPLA (TLR4, all 100 ng/ml), (B) un-
stimulated vehicle to VTX-294 (TLR8, all 0.1 mM), (C) MPLA to
VTX-294 (TLR8, all 0.1 mM) and (C) MPLA to MPLA with
VTX-294, with a modified Human Inflammation MAP v. 1.6-
antigen panel. Data are shown as mean 6 SEM for n=3.
(TIFF)
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